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Abstract
In recent years, large-scale outbreaks of chikungunya arbovirus (CHIKV), which 
is transmitted by the Aedes mosquito, have enabled the rapid propagation of the virus 
across the world. After acute infection phase with commonly fever, joint pain, head-
ache, or rash, chronic rheumatism (arthralgia or myalgia, anorexia, and concentration 
disorders) up to 40% of cases is observed. The chronic form is defined by symptoms 
persisting for more than 3 months, and up to years, after initial diagnosis. Chronic 
discomfort has been linked to one of the four genotypes described. These genotypes 
represent different geographic lineages (classification based on partial sequence of viral 
E1 glycoprotein): West African, East-Central-South-African (ECSA), ECSA-diverged 
or Indian Ocean Lineage (IOL), and Asian. The first marker detected in CHIK infection 
is the viral RNA, usually by reverse transcription-polymerase chain reaction (RT-PCR). 
This marker can be identified in samples within 8 days of symptom onset. The infection 
can also be diagnosed with serological testing to detect CHIKV-specific immunoglobu-
lin IgG and/or IgM. Sequencing studies can determine the infecting genotype.
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1. Introduction
Chikungunya virus (CHIKV) is an emerging mosquito-borne alphavirus that 
causes severe acute febrile infection, often debilitating polyarthralgias and arthri-
tis [1], and its symptoms are similar. The name chikungunya is derived from an 
African language makonde which means “that which bends up” or “stooped walk” 
because of the incapacitating arthralgia caused by the disease.
Chikungunya virus, the first reported case of which was in Tanzania in 1952 [2], 
is endemic in certain parts of West Africa, human serosurveys having identified 
antibodies to chikungunya virus in 35–50% of the population in some areas [3, 4].
1.1 Epidemiology, structure, and classification of chikungunya
Since 2004 CHIKV has spread into novel locations, with outbreaks having 
occurred in other parts of Africa as well as Asia, Europe, and the islands of the Indian 
Current Topics in Neglected Tropical Diseases
2
and Pacific Oceans, and more recently in the Americas, mostly during the tropical 
rainy season. The risk of CHIKV being imported into further new areas is ever pres-
ent because of the high attack rates, which affect between one-third to three-quarters 
of the population in areas where the virus is circulating, associated with the recur-
rence of epidemics, along with the high levels of viremia in infected humans and the 
worldwide distribution of the vectors, Aedes aegypti and Aedes albopictus [4]. Infected 
travelers can import chikungunya into new areas [1, 5–7], and in areas with A. aegypti 
and/or A. albopictus mosquitoes, local transmission can follow.
CHIKV multiple outbreaks have been identified as a cause of dengue-like illness 
with arthralgia in Africa and febrile hemorrhagic disease in Asia [2]. Although 
outbreaks of CHIKV were limited from the 1970s onward, in 2004–2005 the virus 
was detected in Kenya and the islands of the Indian Ocean in 2004–2005 [4, 8–10], 
and in the last decade, there have been massive outbreaks in new areas as well as in 
those where the virus is endemic [11]. What is more, local transmission of CHIKV 
has also been reported for the first time in parts of Europe, Asia [12], Australia [13], 
and America [9, 14, 15].
In the Americas, autochthonous CHIKV transmission was first reported in 
the Caribbean, on the island of St. Martin, in December 2013 [16], from which 
it is known to have spread to 45 countries or regions in Central/South/North 
America, where, according to the Pan American Health Organization, there had 
been 2 million suspected cases by 2014 [17]. It was detected in Central and South 
America in 2014, where there have since been multiple widescale outbreaks [13, 
17], and between June and November of that same year, cases were reported in 
people returning to Northwest Italy from the Caribbean and Central America, even 
though there had been no reported cases of CHIKF in either region for 3 years [18]. 
More recently, in 2016–2017, autochthonous CHIKV transmission was reported in 
India [19], Pakistan [20], and Italy [21]. It can be assumed that the combination of 
increased global travel and trade, the wide distribution of the mosquito vectors, and 
a lack of herd immunity have all contributed to the introduction and rapid spread of 
CHIKV in naïve populations.
Dengue and Zika viruses are transmitted by the same mosquito vectors as chi-
kungunya so all three viruses can co-circulate in a geographic region, and coinfec-
tions have been documented [22, 23]. This clearly has implications for diagnosis in 
the laboratory.
CHIKV belongs to the Togaviridae family, genus Alphavirus, within the Semliki 
Forest antigenic complex. Among the other members of this antigenic complex are 
the Mayaro, O’Nyong-nyong, and Ross River viruses, all of which are capable of 
causing disease in humans [24].
Chikungunya is a positive-sense single-stranded RNA virus with approximately 
12 kb. It is spherical in shape and has a diameter of about 70 nm. The viral particle 
comprises 240 copies of the capsid protein contained within a lipid bilayer envelope 
which has 80 trimer-shaped spikes formed by E1 and E2 glycoproteins protruding 
from it [25]. There are two open reading frames (ORFs) in the genome: the 5’ORF 
(genomic RNA) is responsible for encoding the nonstructural proteins nsP1, nsP2, 
nsP3, and nsP4, and the 3’ORF (subgenomic RNA) is responsible for encoding a 
polyprotein that is processed into the structural capsid and envelope proteins (E1 
and E2) and two peptides (E3 and 6 K) [26].
Several CHIKV genotypes which have been described are shown below: East-
Central-South-African (ECSA) isolates which comprise the East, Central and South 
African, and West Africa isolates (West Africa) and Asian isolates (Asian). The 
Indian Ocean Lineage (IOL) was identified in 2004 as a descendant of the ECSA 
lineage [27, 28].
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1.1.1 Chikungunya genotypes
CHIKV can be genetically classified into three major lineages: West African 
(WA); East, Central, and South African (ECSA); and Asian. Prior to 2004, these 
were rarely found outside the geographic limits implied by their names. The 
epidemics subsequent to 2004 were mainly due to isolates forming a distinct clade 
within the ECSA lineage [29], likely originating in eastern Kenya before spreading 
to cause large outbreaks affecting millions in islands of the Indian Ocean, India, and 
Asia [30], as well as numerous imported cases in previously nonendemic regions, 
including Europe and the Americas. More recently, since 2013, the Asian genotype 
has also caused significant outbreaks in the Caribbean and the Americas.
Additionally, the Indian Ocean (IOL) sublineage emerged within the ECSA 
clade, and the Asian/American sublineage emerged within the Asian clade [31, 32].
While differences in epidemiological and pathological characteristics among 
outbreaks involving different CHIKV lineages and sublineages have been suggested, 
few targeted investigations comparing lineage virulence levels have been reported.
The most important clades in terms of public health impact are the Asian lineage 
(including Asian/American) and the IOL sublineage, as well as some other ECSA 
lineage strains responsible for African outbreaks. They are responsible for multiple 
CHIKV outbreaks over the last 15 years involving millions of people [29, 32, 33], 
which continue to arise in Asia and Africa [34, 35].
CHIKV phylogenetic analysis, based on previous work speculating on the 
existence of distinct lineages [36], has established that the three principal currently 
circulating genotypes emerged from a common ancestor less than 500 years ago and 
that the ECSA and Asian genotypes separated within the past 150 years [29].
West African genotype is particularly well adapted to sylvatic mosquitoes or to a 
certain vector-host combination within the sylvatic cycle.
The Asian genotype that once circulated in India during the 1950s and 1960s 
formed a clade that was phylogenetically distinct from the Southeast Asian (SEA) 
strains that continue to circulate today. There is a remarkable spatial and temporal 
pattern in the evolution of the SEA lineage, spreading from Thailand to Indonesia 
and then to the Philippines and the South Pacific.
2.  Transmission, pathogenesis, clinical disease, and differential 
diagnosis
Chikungunya virus is transmitted to people, as mentioned above, primarily via 
mosquito bites (primarily during the day but also at night). Mosquitoes become 
infected when they feed on a person already infected with the virus and then spread 
the virus to other people via biting, after the virus reaches the mosquito salivary 
glands. Other less-frequent routes of transmission are through blood products, 
organ transplantation, and maternal-fetal.
Pregnant women infected with CHIKV are not at increased risk of atypical or 
severe disease, but maternal CHIKV infection has been associated with miscarriage 
in the first trimester [16, 37, 38]. However, when maternal infection occurs toward 
the end of pregnancy, only 12% of newborns are expected to be symptomatic, 
clinical manifestations—fever, poor feeding, tenderness, unexplained apnea, 
peripheral edema, thrombocytopenia, and rash—appearing 3–7 days after delivery 
[37, 39]. More severe symptoms have also been observed, such as encephalopathy 
and myocardial disease, and neurocognitive development was found to be poor in 
children with perinatal CHIKV infection [40].
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2.1 Clinical disease
The “natural” history of symptomatic CHIKV infection has been classified into 
three phases: acute, post-acute, and chronic.
Acute phase is considered the first 3 weeks of clinical manifestations. The 
incubation period is 3–7 days (range 1–14 days), and clinical manifestations begin 
abruptly, usually with high fever (>39°C), during 3–5 days (range 1–10 days), and 
malaise [41]. More than 85% of patients are symptomatic [1]. The duration of acute 
phase is usually 7–10 days.
Polyarthralgia, commonly bilateral and symmetric, begins 2–5 days after onset 
of fever and involves multiple joints: hands (50–76% of infected individuals), wrists 
(29–81%), ankles (41–68%), and axial skeleton (34–52%) [42, 43]. Pain may be 
intense and disabling, leading to immobilization.
Rash (maculopapular) has been reported in 40–75% of patients [43] and pruri-
tus in 25–50% of patients.
Serious complications are not common, except in patients older than 65 years 
and patients with underlying pathologies, where the infection and symptoms can 
contribute to the cause of death. These severe forms usually involve the central 
nervous system, respiratory system, and urinary system.
Most patients recover fully, but in some cases joint pain may persist, or the patient 
experiences relapses of signs and symptoms for several months or even years [26].
In the post-acute phase, only a small proportion of patients remain completely 
asymptomatic 2–3 weeks after the onset of disease [44]. Generally, most patients 
exhibit only transitory improvements in their clinical condition, and relapses occur 
after a brief “healing” period. Most studies have indicated that, on average, clinical 
manifestations persist in 50–90% of patients after the second or third week, and 
the percentage of patients with persistent polyarthralgia after the acute phase of 
CHIKV infection is more frequent in those older than 40 years and in women [45].
Clinical manifestations observed during the post-acute phase, which indicate 
the persistence of the initial inflammatory process, include arthritis/arthralgia, 
edematous polyarthritis of fingers and toes, morning pain and stiffness, and severe 
tenosynovitis [42].
A set of nonspecific clinical manifestations that are not always associated with 
CHIKV usually occurs, such as chronic fatigue, changes in skin color, alopecia, 
decompensated endocrine and metabolic diseases, as well as the decompensation of 
other preexisting chronic diseases, depression, and anxiety [44].
Chronic phase: It is estimated that the percentage of patients infected with chi-
kungunya virus who progress to chronic phase (more than 3 months) varies from 
40 to 80% [45–47], and they may endure clinical manifestations for a few months 
or even years [44]. Although no clear evidence exists to explain the pathogenesis 
of persistent symptoms following infection, two hypotheses have been proposed: 
(a) That viral and/or antigenic debris remains in the tissues of joints and muscles. 
Unfortunately, to date, the virus has not been isolated from such tissue. However, 
CHIKV proteins have been found in macrophages and muscle cell tissue of relaps-
ing CHIKV patients, supporting the notion that there may be low-grade replication 
of the virus or non-replicative viral debris present. (b) That infection triggers a 
persistent immune response. Studies are underway with mouse models to determine 
whether, and in what way, immunological mechanisms might be altered in patients 
with persistent symptoms [48, 49].
Chronic phase sufferers can be divided into three groups in terms of disease 
progression: those whose symptoms disappear either spontaneously or following 
treatment and who have no long-term complications, which accounts for the major-
ity of such cases; a group who experiences prolonged and persistence generalized 
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clinical symptoms, with or without joint problems; and another set of patients in 
whom the degenerative or inflammatory process is exacerbated and their condition 
becomes serious [44].
Twenty-five percent of CHIKV cases have been estimated to result in chronic 
inflammatory rheumatism, although this study did not address the issue of dif-
ferences between genotypes [50]. Other symptoms, such as chronic pain, mental 
health issues, and nonspecific manifestations, are also common in this phase 
[51–54], with arthralgia and arthritis with pain accompanied by articular edema 
or morning joint stiffness being the most frequent clinical manifestations [55]. 
Tenosynovitis is also frequent (with two or more tendons affected), and less com-
mon symptoms are fatigue and neuritis [44]. Clearly the daily life of patients with 
long-term chronic CHIKV symptoms is considerably impacted [54], and interest-
ingly there is some evidence that the incidence of chronic symptoms is greater 
in high-income than low-income countries, albeit that the confidence intervals 
overlapped [54]. These same authors did consider the relationship between virus 
genotype and self-reported chronic discomfort and found this symptom to be less 
prevalent in those infected by the ECSA group, followed by those carrying the Asian 
strain. The highest prevalence was linked to the ECSA-diverged/IOL genotypes, 
though there was overlap with the Asian strain.
There is no commercial vaccine against CHIKV, although development is under-
way [56–58] and there is no specific antiviral therapy for acute infection. Treatment 
in this phase consists of supportive care for as long as the infection is confirmed. 
It is, however, known that systemic glucocorticoids and other immunosuppressive 
medications should be avoided in patients during acute infection [44].
The management of persistent or relapse symptoms, particularly joint 
disease, depends upon the duration of the symptoms. Treatment with anti-
inflammatory drugs and analgesics is appropriate in the acute phase. On the 
other hand, for symptoms persisting for more than 3 months after infection, the 
use of disease-modifying antirheumatic drug (DMARD) therapy, such as metho-
trexate (MTX) and hydroxychloroquine [44], or, as an alternative, physiotherapy 
is indicated [59].
2.2 Differential diagnosis
Fever and polyarthralgia are key symptoms of CHIKV infection but are far from 
being reliable diagnostic markers since they have a sensitivity of only 84%, a posi-
tive predictive value (PPV) of 71%, and an 83% negative predictive value (NPV) 
[25]. Thus differential diagnosis of both the acute and the chronic manifestations 
of the disease can be complex and take time due to the nonspecific nature of the 
typical symptoms of arthralgia, high fever, and rash. The shared vectors, as well as 
symptoms, of CHIKV and the DENV, ZK, O’nyong-nyong, and Mayaro viruses, as 
well as the fact that the viruses all co-exist and are known to co-infect, mean that 
they must all be ruled out in the differential diagnosis.
Therefore, it is difficult to differentiate from those of other febrile illnesses or 
be misdiagnosed in areas where dengue occurs. Other infections that should be 
considered include malaria, yellow fever, leptospirosis, measles, mononucleosis, or 
African tick bite fever.
An additional diagnostic complication is the similarity of chronic arthralgia 
caused by chikungunya fever with other more common causes, and it has been dem-
onstrated that patients with underlying joint disease prior to CHIKV infection have 
worse prognosis and increased morbidity [60]. Differential serological diagnosis 
includes the exclusion of rheumatoid and systemic arthritis, lupus erythematosus 
Reiter arthritis, rheumatoid arthritis, and hepatitis C.
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It is thus clear that differential diagnosis is essential to establish CHIKV infection 
and ensure the appropriate public health response as well as the optimal treatment 
regime for the patient. Employing a single PCR which targets all three infectious 
agents (CHIKV, DENV, ZV), available from US Centers for Disease Control and 
Prevention (CDC) and approved laboratories, would expediate diagnosis [61–64].
3. Diagnosis
Chikungunya virus infection should be suspected in patients with acute onset of 
fever and polyarthralgia and who meet the relevant epidemiologic exposure criteria 
(residence in or travel to an area where mosquito-borne transmission of chikungu-
nya virus infection has been reported).
The laboratory diagnosis of CHIKV infection can be achieved in the majority 
of cases by following two different strategies: the detection of viral RNA (virologi-
cal diagnosis) and the identification of the specific immune response (serological 
diagnosis). To this end, choosing the appropriate timing of specimen collection 
and of the use of the most suitable diagnostic methodologies is crucial for accurate 
diagnosis. The algorithm developed by the US Center for Disease Control and 
Prevention (CDC) to diagnose CHIKV infections is based on the characteristics of 
CHIKV infection and the timing of specimen collection (Figure 1).
CHIKV replicates rapidly to high titers in the host, and viral RNA gener-
ally can be detected by real-time RT-PCR in the first week after onset of clinical 
illness, while immunoglobulin M (IgM) antibodies are normally detectable in 
serum by days 5–7 after onset of illness [65]. Consequently, the kinetic replica-
tion and pathogenesis of CHIKV infection, including the duration of viremia and 
the response of the host immune response, should be considered when selecting 
the appropriate diagnostic tests [66]. Molecular assays (TaqMan real-time PCR, 
RT-LAMP assay, and reverse transcription PCR) are more sensitive in the early 
stage of chikungunya fever (2–5 days p.o.i.) when CHIKV-specific IgM is not 
yet detectable. In the later stages of chikungunya fever (>5 days p.o.i.), CHIKV-
specific IgM is a more reliable indicator.
Figure 1. 
Time course of chikungunya virus viremia and immune response. Source of CDC.
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In the CHIKV testing algorithm developed by the CDC arbovirus diagnostic 
laboratory, samples collected <6 days after onset of illness are first tested by viro-
logical methods (CHIKV real-time RT-PCR using two different set primers/probe 
that were developed to detect different genotypes (Figure 2)).
The CDC guidelines indicate that samples collected on or after day 6 of ill-
ness and samples with negative real-time RT-PCR results are tested by serological 
methods (the CHIKV IgM antibody-capture enzyme-linked immunosorbent assay 
(MAC-ELISA) or an indirect fluorescent antibody assay (IFA) and plaque reduction 
hemagglutination test as confirmation) [67–70].
3.1 Types of samples for chikungunya infection diagnosis
Samples for chikungunya diagnosis have to be collected as soon as possible. Two 
different types of sample are suitable for virological and/or serological diagnosis.
Viral diagnosis depends on the characteristics of CHIKV infection and the time 
elapsed since the viral infection, the type of patient (e.g., fetus, pregnant, etc.), and 
clinical manifestation of infection. Virological diagnosis can be made using samples 
of blood (whole blood, plasma, or serum), urine, blister fluid, cerebrospinal fluid, 
amniotic fluid, or tissues such as the placenta and brain, among others.
Samples must be collected in strictly aseptic conditions and in the right con-
tainer: sterile recipients for fluids and with transport viral medium for the others 
(blisters, biopsies, swabs, etc.).
Samples need to be sent to the laboratory quickly.
The best type of tube for serological diagnosis is serum separator. Heparin and 
EDTA are unsuitable for antibodies CHIK testing [71]. Serum used for serological 
test can be used for virological diagnosis, but plasma or whole blood (leukocytes) 
is preferable.
Figure 2. 
The Centers for Disease Control and Prevention diagnostic testing algorithm for detection of chikungunya virus 
infection. Source of CDC.
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3.2 Virological diagnosis
As was described above, for virological diagnosis it is important to know the 
pathogenesis and the infection kinetics. The RNA viruses are found in plasma or 
serum specimens between 2 and 6 days following onset of fever, which corresponds 
to the period of incubation [41]. Viral load can subsequently rapidly reach up to 
108/109 genome copies/ml of blood [1, 26, 37].
Complete virions as well as viral fragments (antigen or genome) are frequent in 
this phase, although replication later declines. In line with this kinetic replication, 
three methods can be used in the laboratory: viral isolation and antigen or genomic 
detection.
3.2.1 Viral isolation
Viral isolation is generally a research tool [71–73]. For viral culture it is essential 
to preserve the complete virion. Culture sensitivity for chikungunya virus is high 
only in early infection (during the viremic phase) but drops 5 days after onset of 
illness. As a result, virus isolation is rarely used in the diagnosis of CHIKV infection 
because low sensitivity occurs after only a few days post-infection, and it is time-
consuming and laborious procedure. However, it does allow for the identification 
of the viral strain and can be important for epidemiologic and research purposes. 
Samples where chikungunya virus is suspected should be handled under Biosafety 
Level (BSL) 3 conditions.
A wide variety of cells are used for in vitro CHIKV cultures in order to assess the 
full scope of the disease, including primary human skeletal muscle myoblasts [74], 
human blood monocytes [75], African green monkey kidney (Vero-E6) cells [76], 
and C6/36 (Aedes albopictus clone cells). Of particular interest, given the known 
tropism of chronic CHIKV for bone and synovial tissues, is the use of primary 
human fibroblast-like synoviocytes [77] and human osteoblasts.
Culture on HEL cells is more sensitive, and the presence of a cytopathic effect 
can be observed earlier than in Vero cells [78].
These cultures all need to be maintained under standard conditions.
3.2.2 Antigen detection
There are commercial immunochromatography antigen detection kits which 
detect CHIKV with high sensitivity in the early phase (up to 4–5 days after the onset 
of fever, when blood-enveloping proteins are still present). These tests also have 
high specificity since no cross-reactions with dengue virus are known to exist, and 
the method is straightforward and simple and does not require specially trained 
laboratory personnel [79].
However, a very important issue to consider is what genotype/s the tests 
are capable of detecting since not all detect all the known genotypes. Thus the 
geographical area from which the patient comes, meaning they are more likely 
to have one genotype or another, needs to be taken into account for accurate 
diagnosis (e.g., Okabayashi’s immunochromatography only detects the Asian 
genotype) [80].
These methods are therefore, generally, sensitivity compromised.
3.2.3 Genomic detection (RT-PCR)
The diagnosis of CHIKV infection in the acute phase of infection is typically 
performed by the detection of viral RNA in plasma or serum (or other sample 
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types) by RT-PCR. The viral RNA can be detected by various molecular methods, 
such as nested and real-time PCRs [37].
Conventional and real-time PCRs have been used to amplify nsP1, nsP2, or even 
envelope protein genes (E3, E2, or E1) [81, 82].
Molecular diagnostic tests used for the detection of CHIKV include reverse tran-
scription (RT) and amplification (PCR) assay of fragments in the nsP1, nsP2, nsP3, 
nsP4, or E1 regions of the CHIKV genome, in general by real-time [65, 82–86]. 
Labeled probes or SYBR Green is used for real-time quantification of the amplified 
PCR products [87, 88]. In these assays, the limits of detection range between 0.5 and 
1.5 log10 RNA copies/reaction. Although the detection of positive-strand RNA is 
commonly used for diagnostic purposes, assays to detect negative-strand CHIKV 
RNA have also been developed. These include strand-specific quantitative RT-PCRs 
for nsP1 [89] and nsP3 [90], which use a tagged-primer system to improve PCR 
specificity and accuracy. In comparison to the detection of positive-strand RNA, the 
detection limit for negative-strand RNA assays is slightly decreased, 3 log10 RNA 
copies [91].
While there is an ever-present possibility of CHIKV spreading further in 
developed countries in the Americas and Europe, CHIKV still predominantly 
occurs in resource-limited countries. Loop-mediated isothermal amplification 
(LAMP) amplifies nucleic acid under isothermal conditions without the use of 
a thermal cycler and is a fast, specific, and cost-effective technique [92]; LAMP 
represents a cheaper alternative amplification method, albeit with lower sensi-
tivity than real-time RT-PCR. Monitoring by turbidity as well as observation of 
color change after adding SYBR Green has also been described for the detection 
of CHIKV [85, 92]. Visualization is made with the naked eye, meaning no sophis-
ticated equipment is required, and thus LAMP is especially useful in developing 
countries or in field studies.
Another method, microfluidic lab-on-chip integrating multiplex molecular 
amplification and DNA microarray hybridization, has been developed for the 
simultaneous detection of 26 globally important tropical pathogens such as 
CHIKV, Dengue virus (DENV), and other arboviruses [93]. Such diagnostic capac-
ity provides an effective and rapid means to establish the presence of specific 
potential pathogens.
The CDC protocol for chikungunya infection diagnosis uses two RT-PCRs. The 
nucleotide sequences of the two sets of primers and probes used are listed in Table 1  
[94, 95]. The 3855 primer/probe set is specific to the ECSA genotypes although it is 
Primer/genome 5′ 
position
Nucleotide sequence
CHIKV3855F GAGCATACGGTTACGCAGATAG
CHIKV3957C TACTGGTGATACATGGTGGTTTC + TGCTGGTGACACATGGTGGTTTC
CHIKV3886FAM 
(probe)
ACGAGTAATCTGCGTACTGGGACGTA + 
ACGAGTCATCTGCGTATTGGGACGCA
CHIK856F ACCATCGGTGTTCCATCTAAAG
CHIK962C GCCTGGGCTCATCGTTATT
CHIK908FAM (probe) ACAGTGGTTTCGTGTGAGGGCTAC
Table 1. 
Chikungunya virus oligonucleotide primers and probes used in the Centers for Disease Control and Prevention 
real-time reverse transcription-polymerase chain reaction assays designed to detect CHIKV Asian genotype 
strains.
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capable of detecting both Asian and ECSA genotypes [95]. The 856 primer/probe 
set targets the Asian genotype, which has a slightly higher sensitivity than the 3855 
set, which is prevalent in the Caribbean. This elevated sensitivity makes it a valu-
able tool for confirming diagnosis in samples where CHIKV RNA levels are reduced. 
These characteristics should be taken into account for testing protocols (i.e., which 
sets to use and in what order).
In our experience “in-house” real-time PCR is a useful tool in the chikungunya 
diagnosis. As such, proprietary primers and probe have been designed (Table 2) 
for CHIKV. In addition, for the syndromic diagnosis of imported viral diseases, our 
in-house RT-PCR can also detect other arboviruses such as Zika, dengue, yellow 
fever, and West Nile (Table 2) with sensitivities/specificities comparable to, or even 
superior to, commercially available techniques [63].
Genomic analysis is also used to classify and characterize viruses usually by 
Sanger sequencing method.
The sequencing of envelope E1 (viral structural glycoprotein) is often used for 
phylogenetic analysis. The three principal strains of CHIKV (ECSA, West African, 
and Asian) have been typed by nucleotide sequencing of a portion of the E1 region 
using RT-PCR [96].
Using sequencing studies to examine genomic evolution, it has been deter-
mined that global chikungunya outbreaks since 2005 have occurred as a result 
of a mutation of the ECSA lineage: an alanine-to-valine substitution in the E1 
envelope glycoprotein at position 226 (A226V), which enabled the virus to 
acquire a new mosquito vector, A. albopictus, commonly known as the Asian tiger 
mosquito, conferring increased virus adaptation and replication ability in Aedes 
albopictus.
There are also specific regions that showed nucleotide variability and novel 
mutations making them suitable for phylogenetic analysis in nsP2 and E2 CHIKV 
regions [97].
Virus Name Sequence (5′- 3′) Amplicon size
DEN.ZIK-TR-S AAGGACTAGAGGTTAGAGGAGACCC
Dengue DEN-TR-A GAGACAGCAGGATCTCTGGTCT 83 bp
DEN-FAM AACAGCATATTGACGCTGG
DEN.ZIK-TR-S AAGGACTAGAGGTTAGAGGAGACCC
Zika ZIK-TR-A3 GGCCAGCGTGGTGGAA 96 bp
ZIK-FAM AAACAGCATATTGACG
CHK-TR-S CGGCGACCATTTGTGATCA
Chikungunya CHK-TR-A TTCGTATTCCGTTGCGTTCTG 127 bp
CHK-FAM CCGGCATCCTTGCTA
WN.FA-TR-S GGCTGGGGCAAYGGCT
Yellow fever FA-TR-A CCTCAAACAAACTCATGGATTTG 91 bp
WN-FA-FAM CATGCGCCAAATT
WN.FA-TR-S GGCTGGGGCAAYGGCT
West Nile WN-TR-A CAAGATGGTTCTTCCTATTGCCT 96 bp
WN-FA-FAM CATGCGCCAAATT
Table 2. 
Primers and probes used to detect DENV, CHIKV, ZIKV, YFV, and WNV.
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3.3 Serological diagnosis
A variety of serological methods (hemagglutination inhibition, ELISA, 
complement fixation, and neutralization of viral infectivity using reference serum 
samples) can be used to characterize the alphavirus species [15, 98]. A fourfold 
increase in levels of CHIK virus IgG antibody in serum samples taken during the 
acute and the recovery phase is required to serodiagnosis. However, it is often 
problematic to collect paired samples, and so the existence of CHIKV-specific IgM 
antibodies in acute-phase samples is used instead. Also, patient serum coupled 
with neutralization by reference serum can be taken as definitive proof of the 
presence of CHIKV.
Several serological assays have been developed, the large majority of which 
demonstrate high reliability and specificity. The most common first-line sero-
logical techniques used for CHIKV diagnosis are the enzyme-linked immunosor-
bent assay (ELISA) and indirect immunofluorescence (IFA) assays, and the most 
suitable sample type is serum, generally using 1/100 dilutions. Commercially 
available ELISA tests, for example, have been shown to demonstrate high sen-
sitivity (ranging from 82 to 88%) and specificity in samples from recovering 
patients [99, 100].
The presence of IgM antibodies indicates recent CHIKV infection [41], gener-
ally occurring in samples taken 2 weeks prior to patients becoming symptomatic. 
Detection of specific IgG antibodies, on the other hand, indicates previous CHIKV 
infection, which can be recent or as long ago as several months or years, given the 
persistence of anti-CHIKV IgG antibodies [1].
3.3.1 Enzyme-linked immunosorbent assay
CHIKV-specific IgM and IgG can be detected in serum using enzyme-linked 
immunosorbent assay immunocapture. The first antibodies detected in patients 
with chikungunya fever is CHIKV-specific IgM, which commonly appears 3–8 days 
after the onset of infection and may persist for several months to 2 years. After 
4–10 days since onset of infection, the IgG antibodies become detectable in serum 
and may persist for years (Figure 1) [1] and be potentially lifelong. The chances of 
cross-reactivity between IgG and other viruses of the Semliki antigenic serocom-
plex are less now than in the past due to improvements in test design and procedure, 
but IgG seroconversion (greater than fourfold increase) is still recommended for 
reliable diagnosis. Furthermore, the existence of closely related alphaviruses in the 
area where the patient was infected necessitates the use of plaque reduction neutral-
ization testing to confirm CHIKV infection [101].
ELISA is a rapid and sensitive method largely used for the detection of anti-
CHIKV antibodies. The most common tests used for the diagnosis of CHIKV 
infection are IgM antibody-capture ELISA (MAC- ELISA) and indirect ELISA 
(i-ELISA) for the detection of type M (IgM) and type G (IgG) immunoglobulin, 
respectively [102]. A list of different commercially available ELISA tests is shown 
in Table 3.
Enzyme-linked immunosorbent assays can be used to confirm the presence of 
anti-CHIKV antibodies, with IgM antibody levels highest 3–5 weeks post-infection 
and persisting for up to 2 months.
ELISA is not, however, without its disadvantages: false-positives because of 
cross-reactivity with other alphaviruses (Ross River virus, Barmah Forest virus, 
and Sindbis virus [103]) and its sensitivity being much reduced (4–20%) in serum 
samples taken during the acute phase [104].
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For these reasons, commercially available rapid diagnostic kits often do not 
provide as reliable results as RT-PCR because they all tend to detect host-derived 
anti-CHIKV IgM antibodies. Furthermore, since IgM antibodies are produced later 
in the course of infection than the antigen, this is a less sensitive test and as such can 
delay diagnosis and reduce the effectiveness of disease management [105].
3.3.2 Indirect immunofluorescence
IFA is an accurate and reliable technique widely used for the detection of specific 
anti-CHIK antibodies. IFA reveals the presence of type-specific antibodies against 
CHIKV by detecting the presence of virus antigens in infected cells.
The specificity of commercial IFA tests has been found to range from 75 to 100% 
in serum collected 5–6 days after infection [106]. That said IFA has some shortcom-
ings in that it is laborious and the personnel carrying out the procedure need to be 
specially trained. In addition interpretation of the microscope examination results 
can be rather subjective, and there is no standardization between labs.
3.3.3 Antibody neutralization assay
The neutralization assay is generally used following ELISA or IFA results to con-
firm CHIKV. Neutralization involves the interaction of viral antigens and specific 
antibodies to block infection. The neutralization test requires the mixing of virus 
and serum, and the resulting mixture is then inoculated into cell culture. Inhibition 
of the virus can then be tested, using a variety of methods, after a number of days 
[107]. The microneutralization assay (MNA) evaluates the neutralizing antibodies. 
Although both methods have high specificity and sensitivity, there are disadvan-
tages, namely, they are labor-intensive since only a small number of samples can 
be processed in each run and a Biosafety Level 3 laboratory (BSL-3) is required 
because live virus is being used.
The drawbacks to antibody testing include cross-reactivity with other alpha 
viruses and the problem of it not being able to distinguish between recent past 
and acute infection, as well as the fact that its sensitivity varies between clinical 
settings.
Company IgM IgG Test
Euroimmun + + ELISA
Novatec + / IgM-capture ELISA
Novatec / + ELISA
IBL + / IgM-capture ELISA
IBL / + IgG-capture ELISA
Abcam + + ELISA
DRG + / IgM-capture ELISA
DRG / + ELISA
GenWay + / IgM-capture ELISA
GenWay / + ELISA
Standard diagnostic + + ELISA
Euroimmun + + IFA
Table 3. 
Commercial diagnostic test available for serological diagnosis of CHIKV infection.
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3.4 Diagnosis in other patients
Diagnosis is clearly always important for appropriate patient management, but it 
becomes crucial in several specific circumstances.
3.4.1 Transplantation or transfusion
CHIKV, like other arboviruses, can be transmitted by blood transfusion or 
through organ transplant from infected donors who were asymptomatic at the time 
of donation. Transmission via organ transplantation could also occur since chi-
kungunya viremia (which may exceed 109 RNA copies/ml plasma) is likely prior to 
onset of symptoms [86, 108, 109].
In a case series of Rosso et al., 80% of the patients presented high viral load 
(>106 copies/ml), and none of the solid organ transplant patients with CHIKV 
infection developed graft rejection or died [110].
In these patients, blood and/or tissues are essential in the diagnosis.
3.4.2 Maternal-fetal transmission
Vertical transmission of CHIKV is a possibility and can affect the fetus, both 
congenital and perinatal infection having been demonstrated.
Congenital and perinatal CHIKV infections were reported following delivery to 
mothers with documented viremia accompanied by symptoms of CHIKF [16, 111, 112].
Vertical transmission rate of CHIKV has been estimated to range from 27.7 to 
48.29%, and the same paper found transmission to be increased in mothers experi-
encing viremia at the time of birth. Neonatal symptoms were found to begin within 
3–9 days postpartum, although there is no evidence of any link between birth 
method and incidence of congenital disease [113].
No link between CHIKV exposure in the first trimester of gestation and 
higher miscarriage risk or congenital malformation has been found to date 
[114, 115]. However, infection in the second or third trimester has been linked 
with increased fetal mortality, although the mechanism of this is unclear [111, 
116]. Furthermore, a change in the evolution of neonates vertically infected 
with CHIKV has been seen following the spread of the virus to Indian Oceanic 
regions and Latin America in terms of the previously minor, self-limiting symp-
toms having been replaced by multiple severe manifestations and sometimes 
death [117].
Of particular note is the serious outbreak of CHIKV in 2006 in the Reunion 
Islands where complications were reported, including seizures and abnormal 
MRI scans [118, 119] as well as cardiac defects in almost 50% of patients [119]. 
In infants, these conditions can lead to death in the first year of life if swift and 
targeted medical intervention is not carried out [120, 121]. All patients in this 
outbreak who exhibited symptoms of neuroinvasive disease were infected with 
the A226V variant strain [122].
Virus infection in fetuses can be documented by positive RT-PCR in the amniotic 
fluid, and placenta, and in the cases of miscarriage, the involvement of CHIKV can 
be investigated in the brain or other fetal tissues [40].
3.4.3 Children
The first descriptions of CHIKF in children were made in the 1960s during out-
breaks in India and South Asia [123–127]. In these younger patients, the infection 
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presented as a febrile illness, with rash and joint pain or dengue-like illness, 
hemorrhagic fever, or CSF infection. Asian lineage infection of children resulted 
in a lower frequency of arthralgia than in those infected by the African lineages, 
although hemorrhagic fever was more frequent in children testing positive for the 
former [117].
Lately, in the regions surrounding the Indian Ocean and the expansion of 
CHIKV into the Western Hemisphere, CHIKV-WH infections in children and 
neonates are reported more frequently and with more severe syndromes and 
sequelae [117].
4. Summary
In recent years, large-scale outbreaks of the chikungunya arbovirus 
(CHIKV) have permitted rapid propagation of the virus across the globe. 
CHIKV is transmitted by the Aedes mosquito, and the acute infection phase 
typically results in fever, joint pain, headache or rash, and chronic rheumatism 
(arthralgia or myalgia, anorexia, and concentration disorders) in up to 40% of 
cases.
The chronic form is defined by symptoms which persist for more than 3 months, 
and up to years, after initial diagnosis. The negative impact of CHIKV infection 
on the patient’s health-related quality of life is quite severe and is not limited to 
the acute disease, and the repercussions may last for several months after clinical 
recovery. The highest prevalence of chronic discomfort was linked to one of the 
four genotypes described. These genotypes represent different geographic lineages 
(classification based on partial sequence of viral E1 glycoprotein): West African, 
East-Central-South-African (ECSA), ECSA-diverged or Indian Ocean Lineage, and 
Asian lineage.
The first marker detected in CHIK infection is the viral RNA, usually by 
RT-PCR. This marker can be present in samples taken within 8 days of onset of the 
illness. After this initial acute phase, the infection can also be diagnosed by serologi-
cal detection of CHIKV-IgG and/or IgM-specific immunoglobulin, and sequencing 
studies can determine the infecting genotype.
The correct diagnosis of chikungunya infection enables the disease pro-
gression to be better predicted and patients’ treatment to be more effectively 
managed.
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